Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
NCT07570810Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jun 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD), obesity and type 2 diabetes mellitus (T2DM) comparing 4mg CS0159 with CS0159 Placebo (2 arms). Primary endpoints: Percentage change in body weight relative to baseline at 12 weeks and Changes in energy expenditure at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
linafexor
03
Conditions
non-alcoholic fatty liver disease (NAFLD)obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07570810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570810.